Solabegron Meets Primary Endpoint in Overactive Bladder Study
Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Overactive Bladder (OAB)
OVERACTIVE BLADDER (OAB)
Vibegron Cuts Daily Urge Urinary Incontinence Episodes, Micturitions in OAB Study
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.
Some Nocturia Cases May Be Eased By Restricting Salt Intake
Decreasing salt intake may benefit patients with nocturia who are heavy salt users, according to a new study published in Neurourology and Urodynamics. In a prospective study, Tomohiro Matsuo, MD, and colleagues from Nagasaki University Graduate School of Biomedical Sciences in Nagasaki, Japan, analyzed changes in lower urinary tract symptoms in 321 patients with nocturia…
Overactive Bladder Linked to Prostate Cancer ADT
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
OAB Symptoms Eased With Intravesical Botulinum Toxin
In a small trial, patients receiving 300 U and 500 U of intravesical abobotulinumtoxin A experienced reductions in nocturia episodes at 12 and 24 weeks.
Nocturia, Overactive Bladder Improved With PTNS
In a study, percutaneous tibial nerve stimulation reduced nocturia episodes by 0.8 on average.
Overactive Bladder Treatment: Which Is the Most Cost-Effective Option?
Study authors developed a Markov model with health states based on daily urinary incontinence episodes (UIEs) to compare the cost-effectiveness of onabotulinumtoxinA, implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications, and mirabegron versus BSC for the management of refractory OAB.
Bladder Health Month: An Interview With Brian Stork, MD
The goal of bladder health month is to encourage individuals to engage in dialogue with their healthcare providers about their symptoms and to empower them to actively participate in their care.
Review: Desmopressin Decreases Nocturia Episodes
Desmopressin reduced the number of nocturnal voids by 0.85 compared with placebo.
Nocturia, Daytime Urinary Frequency Linked With Mortality
Men with nocturia have a 1.4-fold greater risk of death than men without nocturia, after adjustment for age and major comorbidities.
Want to read more?
Please login or register first to view this content.
Next post in Overactive Bladder (OAB)
